欧普康视：药品的研发进度将依照规则披露

Core Viewpoint - The company Opucon Vision (300595) has been conducting clinical trials for its atropine eye drops for over a year, with the drug development progress to be disclosed according to regulations [1] Group 1 - The clinical trial for the atropine eye drops has been ongoing for more than a year [1] - The company will disclose the drug development progress in accordance with regulatory requirements [1]